{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:38:55Z","timestamp":1792762735695,"version":"4.5.0"},"reference-count":22,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2026,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"sc_a1\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate long-term clinical outcomes, recurrence rates, and complications following photodynamic therapy (PDT) in horses with immune-mediated keratitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of horses treated with PDT at the Swedish University of Agricultural Sciences Equine Clinic from May 2018 through October 2025 were reviewed retrospectively. Eyes with a clinical diagnosis of recurrent immune-mediated keratitis that had responded to immunosuppressive therapy and been subjected to PDT therapy were included. Infracyanine green was injected intrastromally, followed by irradiation with an 810-nm diode laser. Recurrence, postoperative complications, and follow-up duration were recorded. Recurrence-free survival was estimated using Kaplan-Meier analysis, and associations with recurrence were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>30 eyes from 28 horses were included. Recurrence occurred in 18 of 30 eyes (60.0%); 12 of 30 (40.0%) remained recurrence-free without medication at final follow-up (median, 1,849 days). Recurrence-free survival was 83.1% at 1 year (95% CI, 64.0% to 92.6%) and 49.8% at 2 years (95% CI, 30.2% to 66.6%); median recurrence-free time was 693 days. Postoperative epithelial defects occurred in 22 of 30 eyes (73.3%), and secondary bacterial ulcerative keratitis developed in 4 of 30 (13.3%); all ulcers healed after adjusted treatment. No clear associations between evaluated variables and recurrence were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a4\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PDT provided medication-free disease control in some eyes, particularly during the first postoperative year, but recurrence was common with longer follow-up. Epithelial defects were frequent, although all resolved without major sequelae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a5\">\n                    <jats:title>Clinical Relevance<\/jats:title>\n                    <jats:p>PDT may be useful when prolonged topical treatment is impractical; repeated early fluorescein staining and long-term surveillance are recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/ajvr.26.08.0368","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:55:43Z","timestamp":1792760143000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Infracyanine green photodynamic therapy provides short-term disease control, but recurrence is common in equine immune-mediated keratitis"],"prefix":"10.2460","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8543-9948","authenticated-orcid":true,"given":"Annika","family":"K\u00e4llse","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"K\u00e4llberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-8763","authenticated-orcid":true,"given":"Lena","family":"Str\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Large Animal Surgery, Swedish University of Agricultural Sciences, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"4","key":"B1","series-title":"Vet Ophthalmol","first-page":"233","article-title":"Immune-mediated keratitis in horses: 19 cases (1998-2004)","volume":"8","author":"Gilger BC","year":"2005","unstructured":"Gilger BC, Michau TM, Salmon JH. Immune-mediated keratitis in horses: 19 cases (1998-2004). Vet Ophthalmol. 2005;8(4):233\u2013239. doi:10.1111\/j.1463-5224.2005.00393.x"},{"issue":"5","key":"B2","series-title":"Equine Vet Educ","first-page":"271","article-title":"Nonulcerative keratopathies in the horse","volume":"12","author":"Matthews AG","year":"2000","unstructured":"Matthews AG. Nonulcerative keratopathies in the horse. Equine Vet Educ. 2000;12(5):271\u2013278. doi:10.1111\/j.2042-3292.2000.tb00057.x"},{"issue":"1","key":"B3","series-title":"Vet Ophthalmol","first-page":"10","article-title":"Equine immune-mediated keratopathies","volume":"12","author":"Matthews A","year":"2009","unstructured":"Matthews A, Gilger BC. Equine immune-mediated keratopathies. Vet Ophthalmol. 2009;12(1):10\u201316. doi:10.1111\/j.1463-5224.2009.00740.x"},{"issue":"3","key":"B4","series-title":"Equine Vet J","first-page":"598","article-title":"Clinical features and outcomes of horses presenting with presumed equine immune mediated keratitis to two veterinary hospitals in the United Kingdom and Finland: 94 cases (2009-2021)","volume":"57","author":"Preston JF","year":"2024","unstructured":"Preston JF, Mustikka MP, Priestnall SL, Dunkel B, Fischer MC. Clinical features and outcomes of horses presenting with presumed equine immune mediated keratitis to two veterinary hospitals in the United Kingdom and Finland: 94 cases (2009-2021). Equine Vet J. 2024;57(3):598\u2013610. doi:10.1111\/evj.14213"},{"key":"B5","series-title":"Equine Ophthalmology","first-page":"1","article-title":"Diseases of the equine cornea","author":"Brooks DE","year":"2016","unstructured":"Brooks DE, Matthews A, Clode AB. Diseases of the equine cornea. In: Gilger BC, ed. Equine Ophthalmology. 3rd ed. John Wiley & Sons Inc; 2016:1\u201358."},{"issue":"7","key":"B6","series-title":"Am J Vet Res","first-page":"1067","article-title":"Immunohistochemical and immunopathologic characterization of superficial stromal immune-mediated keratitis in horses","volume":"73","author":"Pate DO","year":"2012","unstructured":"Pate DO, Clode AB, Olivry T, Cullen JM, Salmon JH, Gilger BC. Immunohistochemical and immunopathologic characterization of superficial stromal immune-mediated keratitis in horses. Am J Vet Res. 2012;73(7):1067\u20131073. doi:10.2460\/ajvr.73.7.1067"},{"issue":"1","key":"B7","series-title":"Vet Ophthalmol","first-page":"4","article-title":"Laser scanning in vivo confocal microscopic characterization of equine immune-mediated keratitis","volume":"23","author":"Ledbetter EC","year":"2020","unstructured":"Ledbetter EC, Irby NL. Laser scanning in vivo confocal microscopic characterization of equine immune-mediated keratitis. Vet Ophthalmol. 2020;23(1):4\u201315. doi:10.1111\/vop.12677"},{"issue":"5","key":"B8","series-title":"Vet Ophthalmol","first-page":"674","article-title":"Subconjunctival bone marrow-derived mesenchymal stem cell therapy as a novel treatment alternative for equine immune-mediated keratitis: a case series","volume":"22","author":"Davis AB","year":"2019","unstructured":"Davis AB, Schnabel LV, Gilger BC. Subconjunctival bone marrow-derived mesenchymal stem cell therapy as a novel treatment alternative for equine immune-mediated keratitis: a case series. Vet Ophthalmol. 2019;22(5):674\u2013682. doi:10.1111\/vop.12641"},{"issue":"5","key":"B9","series-title":"Vet Ophthalmol","first-page":"424","article-title":"Subconjunctival autologous muscle-derived mesenchymal stem cell therapy: a novel, minimally invasive approach for treating equine immune-mediated keratitis","volume":"27","author":"Narinx F","year":"2024","unstructured":"Narinx F, Sauvage A, Ceusters J, Grulke S, Serteyn D, Monclin S. Subconjunctival autologous muscle-derived mesenchymal stem cell therapy: a novel, minimally invasive approach for treating equine immune-mediated keratitis. Vet Ophthalmol. 2024;27(5):424\u2013433. doi:10.1111\/vop.13175"},{"issue":"suppl 1","key":"B10","series-title":"Vet Ophthalmol","first-page":"23","article-title":"Treatment of immune-mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices","volume":"17","author":"Gilger BC","year":"2014","unstructured":"Gilger BC, Stoppini R, Wilkie D, et al. Treatment of immune-mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices. Vet Ophthalmol. 2014;17(suppl 1):23\u201330. doi:10.1111\/vop.12087"},{"issue":"8","key":"B11","series-title":"Equine Vet Educ","first-page":"e323","article-title":"Outcome of superficial keratectomy without conjunctival graft as a surgical technique for immune-mediated keratitis in horses: four cases","volume":"34","author":"Dieterman E","year":"2021","unstructured":"Dieterman E, Hermans H, Slenter IJM, Kuijpers NW, Grinwis GCM, Boev\u00e9 MH. Outcome of superficial keratectomy without conjunctival graft as a surgical technique for immune-mediated keratitis in horses: four cases. Equine Vet Educ. 2021;34(8):e323\u2013e330. doi:10.1111\/eve.13589"},{"issue":"6","key":"B12","series-title":"J Am Vet Med Assoc","first-page":"710","article-title":"Standing superficial keratectomy provides long-term control of epithelial and stromal equine immune-mediated keratitis","volume":"264","author":"Toddy T","year":"2026","unstructured":"Toddy T, Ledbetter EC, Knickelbein KE. Standing superficial keratectomy provides long-term control of epithelial and stromal equine immune-mediated keratitis. J Am Vet Med Assoc. 2026;264(6):710\u2013716. doi:10.2460\/javma.25.11.0754"},{"issue":"4","key":"B13","series-title":"Equine Vet Educ","first-page":"e95","article-title":"The long-term outcomes of standing superficial keratectomy as the sole treatment of corneal B-cell lymphoma in five horses in the UK: clinical, histopathology, immunohistochemical and molecular findings","volume":"36","author":"De Oliveira F","year":"2024","unstructured":"De Oliveira F, Scurrell EJ, Dixon S, Lowe R. The long-term outcomes of standing superficial keratectomy as the sole treatment of corneal B-cell lymphoma in five horses in the UK: clinical, histopathology, immunohistochemical and molecular findings. Equine Vet Educ. 2024;36(4):e95\u2013e103. doi:10.1111\/eve.13917"},{"issue":"1","key":"B14","series-title":"Vet Ophthalmol","first-page":"e70027","article-title":"Infracyanine green-based photodynamic therapy for immune-mediated keratitis in horses","volume":"29","author":"Lam KP","year":"2026","unstructured":"Lam KP, Keys DA, McMullen RJ. Infracyanine green-based photodynamic therapy for immune-mediated keratitis in horses. Vet Ophthalmol. 2026;29(1):e70027. doi:10.1111\/vop.70027"},{"issue":"9","key":"B15","series-title":"World J Gastrointest Surg","first-page":"1841","article-title":"Indocyanine green dye and its application in gastrointestinal surgery: the future is bright green","volume":"15","author":"Lim ZY","year":"2023","unstructured":"Lim ZY, Mohan S, Balasubramaniam S, Ahmed S, Siew CCH, Shelat VG. Indocyanine green dye and its application in gastrointestinal surgery: the future is bright green. World J Gastrointest Surg. 2023;15(9):1841\u20131857. doi:10.4240\/wjgs.v15.i9.1841"},{"key":"B16","series-title":"Photodynamic Therapy: New Research","first-page":"3","author":"Garrier J","year":"2013","unstructured":"Garrier J, Reshetov V, Zorin V, Guillemin F, Bezdetnaya L.  Contrasting facets of nanoparticles-based phototherapy: photo-damage and photo-regeneration In: Elsaie MLT, ed. Photodynamic Therapy: New Research. 1st ed. Nova Science Publishers; 2013:3\u201311."},{"issue":"4","key":"B17","series-title":"CA Cancer J Clin","first-page":"250","article-title":"Photodynamic therapy of cancer: an update","volume":"61","author":"Agostinis P","year":"2011","unstructured":"Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250\u2013281. doi:10.3322\/caac.20114"},{"issue":"2","key":"B18","series-title":"J Porphyr Phthalocyanines","first-page":"105","article-title":"Basic principles of photodynamic therapy","volume":"5","author":"Macdonald IJ","year":"2000","unstructured":"Macdonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J Porphyr Phthalocyanines. 2000;5(2):105\u2013129. doi:10.1002\/jpp.328"},{"issue":"8","key":"B19","series-title":"RSC Adv","first-page":"7204","article-title":"The application of ICG-based photodynamic therapy combined with nanotechnology in tumor treatment","volume":"16","author":"Fu H","year":"2026","unstructured":"Fu H, Zhao L, Tang D. The application of ICG-based photodynamic therapy combined with nanotechnology in tumor treatment. RSC Adv. 2026;16(8):7204\u20137220. doi:10.1039\/d5ra08557h"},{"issue":"3","key":"B20","series-title":"Photochem Photobiol Sci","first-page":"397","article-title":"Polymethine dyes for PDT: recent advances and perspectives to drive future applications","volume":"21","author":"Dereje DM","year":"2022","unstructured":"Dereje DM, Pontremoli C, Moran Plata MJ, Visentin S, Barbero N. Polymethine dyes for PDT: recent advances and perspectives to drive future applications. Photochem Photobiol Sci. 2022;21(3):397\u2013419. doi:10.1007\/s43630-022-00175-6"},{"issue":"8","key":"B21","series-title":"Pharmaceutics","first-page":"1147","article-title":"Photodynamic therapy and hyperthermia in combination treatment-neglected forces in the fight against cancer","volume":"13","author":"Bienia A","year":"2021","unstructured":"Bienia A, Wieche\u0107-Cudak O, Murzyn AA, Krzykawska-Serda M. Photodynamic therapy and hyperthermia in combination treatment-neglected forces in the fight against cancer. Pharmaceutics. 2021;13(8):1147. doi:10.3390\/pharmaceutics13081147"},{"issue":"5","key":"B22","series-title":"Equine Vet J","first-page":"1380","article-title":"Photodynamic therapy with infracyanine green induces keratocyte depopulation in the normal equine cornea","volume":"58","author":"Rogers CM","year":"2026","unstructured":"Rogers CM, Ledbetter EC, Reid AM, Scott EM, Knickelbein KE. Photodynamic therapy with infracyanine green induces keratocyte depopulation in the normal equine cornea. Equine Vet J. 2026;58(5):1380\u20131389. doi:10.1002\/evj.70159"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.26.08.0368\/ajvr.26.08.0368.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/aop\/ajvr.26.08.0368\/ajvr.26.08.0368.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:55:43Z","timestamp":1792760143000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.26.08.0368\/ajvr.26.08.0368.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2460\/ajvr.26.08.0368","relation":{},"ISSN":["0002-9645","1943-5681"],"issn-type":[{"value":"0002-9645","type":"print"},{"value":"1943-5681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]}}}